Trials / Unknown
UnknownNCT02787837
PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Prospective Multi-Centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 220 (estimated)
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
PROSABI is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with abiraterone
Detailed description
This study is a prospective biomarker study of patients with mCRPC undergoing treatment with abiraterone as standard of care treatment. The participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.
Conditions
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2018-04-01
- Completion
- 2020-12-01
- First posted
- 2016-06-01
- Last updated
- 2020-01-27
Locations
24 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02787837. Inclusion in this directory is not an endorsement.